Forbes January 25, 2022
Today, Cellino Biotech, an autonomous cell therapy manufacturing company, announced an $80 million Series A financing round led by Leaps by Bayer along with 8VC, Humboldt Fund, and new investors including Felicis Ventures and Khosla Ventures, that could fix a problem holding the biotech industry back. Cellino plans to expand access to stem cell-based therapies with a goal to build the first autonomous human cell foundry in 2025.
To understand why this matters, you have to look at the history of drug development. During the last 20 years, drug development has moved from making small molecules and chemicals, such as aspirin, that can have an impact on biology to biologicals like proteins, antibodies, and most recently RNA vaccines. The next...
Today's Sponsors
Today's Sponsor